Rovi/€ROVI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
Ticker
€ROVI
Sector
Primary listing
BME
Employees
2,188
Headquarters
Website
Rovi Metrics
BasicAdvanced
€3.1B
23.24
€2.59
0.47
€0.76
1.26%
Price and volume
Market cap
€3.1B
Beta
0.47
52-week high
€78.65
52-week low
€45.52
Average daily volume
25K
Dividend rate
€0.76
Financial strength
Current ratio
2.768
Quick ratio
0.976
Long term debt to equity
17.636
Total debt to equity
22.498
Dividend payout ratio (TTM)
42.68%
Interest coverage (TTM)
56.91%
Profitability
EBITDA (TTM)
194.512
Gross margin (TTM)
62.40%
Net profit margin (TTM)
17.66%
Operating margin (TTM)
23.05%
Effective tax rate (TTM)
22.75%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
12.50%
Return on equity (TTM)
25.01%
Valuation
Price to earnings (TTM)
23.238
Price to revenue (TTM)
4.104
Price to book
5.41
Price to tangible book (TTM)
5.72
Price to free cash flow (TTM)
42.592
Free cash flow yield (TTM)
2.35%
Free cash flow per share (TTM)
1.412
Dividend yield (TTM)
1.26%
Forward dividend yield
1.26%
Growth
Revenue change (TTM)
-3.73%
Earnings per share change (TTM)
-8.80%
3-year revenue growth (CAGR)
0.45%
10-year revenue growth (CAGR)
11.91%
3-year earnings per share growth (CAGR)
-8.23%
10-year earnings per share growth (CAGR)
18.91%
3-year dividend per share growth (CAGR)
-0.72%
10-year dividend per share growth (CAGR)
18.66%
What the Analysts think about Rovi
Analyst ratings (Buy, Hold, Sell) for Rovi stock.
Bulls say / Bears say
ROVI’s Q1 2025 EBITDA of €30.3 million surpassed the consensus estimate of €27 million, leading to about a 6% increase in its share price as investors responded positively to the earnings beat and the announcement of a €36.3 million R&D grant (Reuters)
Analysts attributed ROVI’s Q1 outperformance to robust results from its heparin franchise, highlighting a concentration of backlog during the quarter that lifted sales in this high-margin division (Reuters)
ROVI’s 2030 guidance projects operating revenue to increase 1.5x to 1.8x from 2024 levels and CDMO revenue to reach around €700 million, reflecting management’s strong confidence in medium-term growth prospects (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Rovi Financial Performance
Revenues and expenses
Rovi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rovi stock?
Rovi (ROVI) has a market cap of €3.1B as of September 10, 2025.
What is the P/E ratio for Rovi stock?
The price to earnings (P/E) ratio for Rovi (ROVI) stock is 23.24 as of September 10, 2025.
Does Rovi stock pay dividends?
Yes, the Rovi (ROVI) stock pays dividends to shareholders. As of September 10, 2025, the dividend rate is €0.75743 and the yield is 1.26%. Rovi has a payout ratio of 42.68% on a trailing twelve-month basis.
When is the next Rovi dividend payment date?
The next Rovi (ROVI) dividend payment date is unconfirmed.
What is the beta indicator for Rovi?
Rovi (ROVI) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.